



The 13th European Nutrition Conference (FENS 2019) was held at the Convention Centre, Dublin on 15–18 October 2019

Conference on ‘Malnutrition in an Obese World: European Perspectives’ Postgraduate Competition

Low and reduced carbohydrate diets: challenges and opportunities for type 2 diabetes management and prevention

Chaitong Churuangsuk^{1,2*} , Michael E. J. Lean¹ and Emilie Combet¹

¹Human Nutrition, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, New Lister Building, Glasgow Royal Infirmary, 10-16 Alexandra Parade, Glasgow G31 2ER, UK

²Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand

Low-carbohydrate diets (LCD) have been promoted for weight control and type 2 diabetes (T2D) management, based on an emerging body of evidence, including meta-analyses with an indication of publication bias. Proposed definitions vary between 50 and 130 g/d, or <10 and <40 % of energy from carbohydrate, with no consensus on LCD compositional criteria. LCD are usually followed with limited consideration for other macronutrients in the overall diet composition, introducing variance in the constituent foods and in metabolic responses. For weight management, extensive evidence supports LCD as a valid weight loss treatment, up to 1–2 years. Solely lowering carbohydrate intake does not, in the medium/long term, reduce HbA1c for T2D prevention or treatment, as many mechanisms interplay. Under controlled feeding conditions, LCD are not physiologically or clinically superior to diets with higher carbohydrates for weight-loss, fat loss, energy expenditure or glycaemic outcomes; indeed, all metabolic improvements require weight loss. Long-term evidence also links the LCD pattern to increased CVD risks and mortality. LCD can lead to micronutrient deficiencies and increased LDL-cholesterol, depending on food selection to replace carbohydrates. Evidence is limited but promising regarding food choices/sources to replace high-carbohydrate foods that may alleviate the negative effects of LCD, demanding further insight into the dietary practice of medium to long term LCD followers. Long-term, high-quality studies of LCD with different food sources (animal and/or plant origins) are needed, aiming for clinical endpoints (T2D incidence and remission, cardiovascular events, mortality). Ensuring micronutrient adequacy by food selection or supplementation should be considered for people who wish to pursue long-term LCD.

Carbohydrate-restricted diet: Ketogenic diet: Macronutrients: Obesity: Type 2 diabetes

Low-carbohydrate diets (LCD) have been heavily promoted for weight management, and as a possible strategy for type 2 diabetes (T2D) management and prevention^(1–3). Current and emerging evidence from randomised trials remains inconclusive regarding the effectiveness of LCD for health benefits (via weight control or metabolic control)⁽⁴⁾. As with any restrictive diet, the

long-term sustainability of LCD has been questioned, with additional concerns over safety, by comparison with current usual western diets or with alternative dietary recommendations^(5–7). This review explores the current evidence and debates which supports or challenges the use of LCD for T2D management and prevention.

Abbreviations: ASCVD, atherosclerotic cardiovascular disease; GLP-1, glucagon-like peptide-1; LCD, low-carbohydrate diet; LFD, low-fat diet; LCHP, low-carbohydrate, high-protein; RCT, randomised controlled trials; RR, relative risk; T2D, type 2 diabetes.

*Corresponding author: Chaitong Churuangsuk, email c.churuangsuk.1@research.gla.ac.uk

Type 2 diabetes: a disease process of obesity

T2D is primarily a nutritional disease, which used to be rare in pre-industrial societies, but is now emerging as one of the most common and damaging chronic diseases. Its global prevalence has approximately doubled from 1980 to 2014, in line with rising overweight and obesity⁽⁸⁾. It causes 1.6 million premature deaths annually, and shortened lives often end with years of pain and multiple disabilities⁽⁹⁾.

The extraordinary association between T2D and elevated BMI (not simply BMI >30 kg/m²) was shown graphically in the prospective Nurses Health Study. Compared to BMI <22 kg/m², women with BMI 23–23.9 kg/m² had a 3.6-time higher relative risk of incident T2D, rising to about 60 times higher risk in women with BMI ≥35 kg/m², levels strongly indicative of a causal relationship^(10,11). Excessive body fat accumulation is a critical, but reversible factor underlying T2D and metabolic syndrome development. In people who are predisposed (for genetic and other reasons), fat accumulates in ectopic sites including liver and pancreas, which damages organ functions⁽¹²⁾, (Fig. 1). Reversing that process by weight loss of at least 3–7% is a key mechanism to prevent or delay onset of T2D^(13–16), and remission of established T2D can be achieved by greater loss, >15% for greatest success, with an intensive weight management programme⁽¹⁷⁾.

Lifestyle modification, through dietary change and increasing physical activity, to halt or delay the disease-process which is driven by weight gain and excess body fat in susceptible individuals, is fundamental for T2D prevention and management⁽¹³⁾. Advice and support for affected individuals can be very effective^(17,18) but is strongly undermined by effective social marketing driving greater energy intake, while physical activity continues to fall in the post-industrial environment⁽¹⁹⁾. Self-reported food consumption by individuals with overweight and obesity can also be misleading, with notable underreported food energy intake (about 418.4 kJ/d) in adults with BMI >30 kg/m²^(20,21). Meanwhile, food disappearance data show consistent positive relationships between rising obesity, increasing energy intake and consumptions of all food groups and all macronutrients^(22–25).

Role of carbohydrate in the diet

A primary role of carbohydrates is to serve as a main and preferable source of body energy, contributing toward approximately half the daily energy intake at population level^(26,27). Carbohydrate-rich foods, consumed regularly everyday as part of our main diets, are considered staple foods, including potatoes, rice and whole grains, breads and pasta. Carbohydrates are also found in fruit, milk, beans and some starchy vegetables⁽²⁸⁾. After consumption, foods containing carbohydrates are digested by the enzymes in the small intestine and absorbed in the form of glucose molecules. Glucose absorbed into the blood stream is transported into cells with the help of insulin, then directly converted to energy or stored as




Fig. 1. (Colour online) Schematic diagram of weight gain and type 2 diabetes (T2D) development.

glycogen⁽²⁸⁾. Not all carbohydrates are digested in the small intestine, with undigested constituents passing to the large intestine (colon); these are classified as dietary fibre⁽²⁸⁾. Dietary fibre can be fermented by the resident bacteria in the large intestine, forming SCFA and also carry out a functional role through water absorption and bulking of stools⁽²⁸⁾. Carbohydrate-rich foods are also a good source of vitamins and minerals, as they come from plant sources. In the UK, cereals and cereal products, vegetables and potatoes and fruits are the major food groups contributing to vitamins and minerals intakes, either naturally presented or fortified (Table 1)⁽²⁶⁾.

Not all carbohydrates are the same, and types and quality matter. Eating carbohydrate-rich foods such as wholegrain, whole-wheat pasta, brown rice, potatoes with skin, fruit and vegetables is associated with chronic disease risk reduction, which is partly explained by dietary fibre, found in plant cell walls⁽²⁹⁾. Fibre can help with body weight maintenance through the regulation of energy balance and satiety^(30,31). Fibre also impacts on bowel health, with decreased risk of constipation⁽²⁹⁾. In contrast, the consumption of free sugars (table sugar, fruit juice, honey, sugar-sweetened beverages or sugary snacks) could result in excess energy intake leading to overweight and obesity⁽³²⁾.

National nutrition surveys in the UK and USA found that ultra-processed foods (NOVA classification) accounted for 65–90% of energy intakes from sugars, and about 50% of total energy intake^(33,34). Ultra-processed foods often have high fat and salt contents, and include highly processed refined carbohydrates which are low in fibre (e.g. white starch)⁽³⁵⁾. A controlled in-patient metabolic ward randomised controlled trials (RCT) of *ad libitum* intake showed that more calories were consumed with a diet offering ultra-processed foods, compared to unprocessed foods, resulting in 1 kg weight gain over 2 weeks⁽³⁶⁾.

What are low-carbohydrate diets?

Prominent media coverage has promoted the idea that obesity and metabolic diseases derive almost entirely



Table 1. Percentage contribution of carbohydrate foods groups to average daily vitamins and minerals intakes in UK adults aged 19-64 years (National Diet and Nutrition Survey (NDNS) 2008-2014)

Food groups	Energy	CHO	Free sugars*	Fibre (NSP)	Vit A	Vit B1	Vit B2	Vit B3	Vit B6	Folate	Vit B12	Vit C	Vit D	Vit E	Iron	Ca	Mg	I	Se	Zn
Cereals and cereal products	31	45	21	39	8	35	22	25	17	27	7	4	13	19	39	31	28	11	27	25
Vegetables and potatoes	11	14	2	31	32	21	6	8	20	26	1	37	2	20	17	7	16	5	6	11
Fruit	3	6	1	9	1	3	2	1	6	4	0	19	0	5	2	2	5	2	1	2
Milk and milk products	9	5	6	1	14	6	28	7	8	7	33	6	5	4	1	36	10	33	6	15
Sugar, preserves and confectionary	5	7	26	1	1	1	2	1	0	1	1	1	0	2	2	2	2	2	1	1

CHO, carbohydrate; Vit, vitamin; Ca, calcium; Mg, magnesium; I, iodine; Se, selenium; Zn, zinc.

* From non-milk extrinsic sugars.

Darker shades highlight a higher contribution of the food group to the UK adult intake for each specific nutrient, based on the UK NDNS data.

from the consumption of sugar, and because all carbohydrates are digested as sugars, from any dietary carbohydrate. The promotion of LCD, with unlimited fat (including saturated fats) and protein stems from this paradigm; for example, the Atkins diet, which limits intakes of bread, pasta and rice, allows unlimited consumption of animal foods such as red meat and processed meat, high in SFA⁽³⁷⁾. While calories from sugar (free sugar, added sugar) are largely unnecessary, total carbohydrate restriction could also entail avoiding health-promoting constituents of high-carbohydrate foods such as whole grains.

Definitions of LCD in the scientific literature vary, and may reflect either diets low in carbohydrate as percentage of energy intake, or low absolute daily consumption (g) of carbohydrate. Commonly used definitions for human subjects range from intakes below 20% to below 45% of energy, and from below 60 g to below 120 g carbohydrate daily⁽³⁸⁻⁴²⁾. Some authors propose referring to LCD as carbohydrate below 40%⁽⁴³⁾ or 26%⁽¹⁾ of energy, and to very-LCD when carbohydrate is under 20%⁽⁴³⁾ or under 10%⁽¹⁾ of energy, with no consensus to date (Table 2). The term LCD is commonly applied regardless of other macronutrient contents in the overall diet composition, which introduces variance in the constituent foods being used, and in metabolic responses. For example, a low-carbohydrate, high saturated fat diet increased LDL-cholesterol⁽⁴⁴⁾, whereas a low-carbohydrate, low saturated fat, high unsaturated fat diets showed no change in LDL-cholesterol⁽⁴⁵⁾. Another study of plant-based LCD with low saturated/high unsaturated fat contents also reported a reduction in LDL-cholesterol⁽⁴⁶⁾.

In addition, there are many different commercial versions of the LCD, such as the Atkins diet, Zone diet or the South Beach diet^(47,48). The most popular have been based on the Atkins diet, with 17 million copies of *Dr Atkins New Diet Revolution* sold, and heavy promotion in the media and on the internet^(37,49,50). This diet suggests two phases. The induction phase limits intake of carbohydrate to no more than 20 g, with liberal intake of fat and protein including red meat, butter and vegetable oils and exclusion of bread, pasta, grains, fruit, other starchy vegetables and dairy products except cheese, cream and butter. Supplementary multivitamins and fibre are recommended. In the second phase, once a desirable weight has been achieved, daily carbohydrate intake can be increased to the level that can maintain weight⁽³⁷⁾.

Hypothesis about low-carbohydrate diets and obesity and type 2 diabetes

Common features among obesity, T2D and metabolic syndrome are hyperinsulinemia and insulin resistance. Instead of excessive total energy intake causing weight gain, insulin resistance and hyperinsulinemia, a carbohydrate-insulin model of obesity hypothesises that carbohydrate intake, including refined starchy foods

Table 2. Proposed definitions of low-carbohydrate diets (LCD)

Categories	Frigolet ⁽⁴³⁾	Feinman ⁽¹⁾	Examples
Very low-carbohydrate (ketogenic) diet	<20 % E or <20–50 g/d	<10 % of the 8368 kJ/d diet or 20–50 g/d	Atkins diet (Induction phase)
LCD	20–40 % E	<26 % E or <130 g/d	Zone diet
Moderate-carbohydrate diet	–	26–45 % E	
High-carbohydrate diet	–	>45 % E	

E, energy.

and sugars causes postprandial hyperinsulinemia, promotes lipogenesis leading to a decreased level of metabolic fuels (glucose and lipids), and leads to weight gain through increased hunger and less energy expenditure⁽⁵¹⁾. By this carbohydrate-insulin model, LCD could reduce postprandial insulin secretion, promote fat loss and decrease risks of chronic diseases⁽⁵¹⁾.

Weight loss with either LCD or low-fat diet (LFD) showed an improvement in insulin resistance, measured by an intravenous glucose tolerance test or euglycaemic-hyperinsulinemic clamp^(52,53). In contrast, non-weight loss, controlled feeding, short-term studies of very-low carbohydrate, high fat (high saturated fat) diets in healthy young men showed worsened insulin sensitivity, measured by oral glucose tolerance⁽⁵⁴⁾, intravenous glucose tolerance test⁽⁵⁵⁾ and euglycaemic-hyperinsulinemic clamps^(56,57). Conversely, short-term studies in healthy postmenopausal women with overweight and obesity⁽⁵⁸⁾, and men with T2D⁽⁵⁹⁾ showed no difference in insulin sensitivity by an euglycaemic-hyperinsulinemic clamp between LCD and LFD, this might be explained by the unsaturated fatty acids used to replace carbohydrate⁽⁶⁰⁾.

The evidence of LCD on β -cell function is limited. One short-term crossover RCT of LCD *v.* normal diet showed a reduction in the first-phase insulin response after 3-d very low-carbohydrate, high-fat diet in healthy young men⁽⁵⁴⁾. In animal studies, long-term ketogenic diets in mice showed an increased insulin resistance, did not prevent β -cell mass decline⁽⁶¹⁾ and even showed a reduction in β -cell mass, including smaller size of islets⁽⁶²⁾. Although LCD could reduce postprandial glucose and postprandial insulin response, without weight loss, the limited evidence fails to support that LCD could reverse pathophysiology of hyperglycaemia in obesity and T2D.

Opportunities for the use of low-carbohydrate diets for diabetes prevention in individuals with overweight and obesity, who are at high risk of type 2 diabetes

Weight management, either weight loss or weight maintenance, plays the biggest role in T2D prevention in individuals with overweight and obesity. Several large diabetes prevention trials have shown a clear benefit on T2D risk reduction principally by modest weight loss

mainly by lowering fat intake (<30 % energy). Other lifestyle modifications have more modest values^(13–16). While weight loss by LFD has been largely incorporated in diabetes prevention trials, RCT of LCD for weight loss do not have long enough follow-up to evaluate incident T2D and were not designed to study incident T2D as a primary outcome. As weight loss is an essential mechanism for T2D risk reduction, this section also discusses the role of LCD in weight loss.

The idea of LCD for weight loss first attracted public interest with the letter of William Banting published in 1863 describing his successful personal weight loss of 46 lbs (about 20 kg), from 202 lbs to 156 lbs over a 12-month period, by cutting bread, potato, pastry, milk, sugar and a majority of fruit⁽⁶³⁾. Several anecdotal reports of similar success have been discussed in the media^(64–66), highlighting that the successful weight loss stories with LCD could be subject to survival bias, with the experience of those who tried and failed not being reported. LCD can achieve a mean weight loss of 7 kg approximately over 6–24 months, up to 10 % of baseline body weight in non-controlled studies^(67–70). LCD, however, certainly work for some, as highlighted in the DIETFITS study that participants who assigned to the LCD group lost a maximum of 30 kg body weight, while some participants gained up to 10 kg body weight⁽⁴²⁾.

Randomised controlled trials and meta-analyses evidence of low-carbohydrate diets for weight loss

Several RCT and meta-analyses have been conducted to examine the effects of LCD for weight loss, compared to LFD^(71–73). The conclusion has repeatedly been that there may be marginally greater weight loss in the short term (approximately the 2 kg expected from the depletion of glycogen and its associated water), but no consistent superiority of LCD over the longer term⁽⁴⁾. At 6 months (Fig. 2a), meta-analyses reported that weight loss from LCD was greater than LFD by 0.7 to 4 kg, but this difference dropped to 0.5 to 1 kg at 12 months, Fig. 2b^(4,40,41,47,71,74).

Factors contributing to inconsistent findings among published meta-analyses of low-carbohydrate diets and low-fat diets for weight loss

Our recent systematic review of published meta-analyses⁽⁴⁾ explores these inconsistent findings regarding the effectiveness of LCD and LFD for weight loss, partly explained by large differences in methodology. Definitions of what constitutes LCD varied among meta-analyses, ranging from 20 g/d to <45 % energy from carbohydrate. The more extreme carbohydrate restriction (20–60 g/d or 10–20 % energy) resulted in greater weight loss compared to LFD⁽⁴⁾. With unrestricted energy LCD, participants typically consumed 30 % less total energy than baseline, resulting in a greater weight loss over 3–6 months^(72,73,75). The weight loss is then attenuated over time (12 months or more), probably via the loss of adherence, as commonly occurs in weight loss trials in free-living participants who tend to return to




Fig. 2. Mean differences in weight loss between low-carbohydrate diet (LCD) *v.* low-fat diet (LFD) at 6 months (a) and 12 months (b) of each meta-analysis (adapted from Churuangasuk *et al.* ⁽⁴⁾). Horizontal axis indicates mean differences in weight loss (kg) between LCD and LFD. The minus value indicates that LCD is more effective for weight loss than LFD.

their previous diet and lifestyle in the obesogenic environment^(76,77).

Quality and bias among published meta-analyses of low-carbohydrate diets and low-fat diets for weight loss

We also assessed the quality of each published meta-analyses using AMSTAR 2 criteria⁽⁷⁸⁾. Contrasting with the wide popularisation and mediatisation of LCD, only two meta-analyses were ‘high quality’ (n 2/10) and they reported no weight loss difference compared to LFD, while half (n 5/10) were of ‘critically low quality’ but reported LCD superiority over LFD for weight loss, up to 4 kg difference⁽⁴⁾. Of particular interest, meta-analyses favouring LCD but of low quality also had higher citations ($\rho = -0.9$, $P = 0.037$), suggesting that public and scientific communities might be responding most to findings generated through poor methodology⁽⁴⁾. Despite featuring at the top of the evidence hierarchy, meta-analyses remain open to biases.

Predictors of weight loss: macronutrients and/or diet adherence – findings from controlled feeding studies and free-living participants

LCD have been promoted on the basis that they theoretically reduce more body fat than LFD, via lessened stimulation of postprandial insulin secretion, leading to lessened inhibition of lipolysis. This hypothesis is, to date, not supported by a meta-analysis of controlled feeding studies comparing the effect of isoenergetic LCD *v.* LFD, with equal protein⁽⁷⁹⁾. A strength of the controlled feeding studies is of the by-passing of adherence as a confounder. The pooled results showed that LFD yielded a 108.764 kJ/d greater difference in energy expenditure, and a 16 g/d greater loss in body fat change, compared to LCD with equal protein⁽⁷⁹⁾. However, these differences are small and could not infer the clinical impact of the effect of dietary fat and carbohydrate on body weight loss, when energy intake is equally held between the two diets. Consistent findings were also seen in weight loss trials in free-living participants. A meta-analysis of LCD *v.* isoenergetic LFD⁽⁷⁴⁾

reported little difference in body weight loss between the two diets at 3–6 months (mean difference -0.74 kg; 95% CI -1.49 , 0.01) and 1–2 years (mean difference -0.48 kg; 95% CI -1.44 , 0.49). This highlights that caloric restriction and adherence to the programme are superior for weight loss than macronutrients composition.

Macronutrients, appetite and weight control

Given that controlled metabolic studies find no difference in weight loss with low or high carbohydrate diets⁽⁷⁹⁾, the small short-term weight-loss advantage of LCD over high-carbohydrate energy-restricted diets in free-living people may be due to greater ease, willingness or enthusiasm to restrict high-carbohydrate foods. High carbohydrate foods are also somewhat easier to identify^(80,81), as much fat in foods is hidden (e.g. in cakes, biscuits, muffin, pizza, cereal bars)⁽⁸²⁾, and this approach is currently heavily promoted via the mainstream and social media. In principle, restricting fat (37–656 kJ/g) should be more effective than restricting carbohydrate (16.736 kJ/g). It is however possible that the higher protein intake from Atkins-style LCD could suppress appetite^(83–86).

A further oft-cited possibility is that the ketosis that develops with more extreme carbohydrate restriction, suppresses appetite^(86,87). When body fat or dietary fat is oxidised, with weight loss or with a very-HFD, the fat oxidation products (ketone bodies) accumulate in the blood stream (e.g. β -hydroxybutyrate, 0.3–0.8 mm on LCD *v.* about 0.1 mm on typical diets with 50% energy carbohydrate)^(88,89). Ketone body production is a biochemically necessary accompaniment of weight loss, and appetite usually increases with energy restriction and starvation^(90,91), as a powerful survival mechanism. Very limited evidence has examined the specific effect of raising ketone bodies to be able to confirm or refute this theory, which is highly relevant to the sustainability of carbohydrate restriction and appetite control. Stubbs *et al.*⁽⁹²⁾ recently published a crossover RCT of exogenous ketone (via a ketone ester drink) compared to a dextrose drink. Ketone ester ingestion markedly




Fig. 3. (Colour online) Proposed relationships between carbohydrates (CHO), dietary fibre, ketones and propionate levels and satiety. E, energy.

increased the blood β -hydroxybutyrate level from 0.2 to 3.3 mM after 60 min, and suppressed reported hunger and desire to eat (both measured by visual analogue scales) by 50% compared to a dextrose drink, 1.5 to 4 h postprandially⁽⁹²⁾.

There is current interest in the evidence that some carbohydrates, functioning as dietary fibre, can suppress appetite and weight gain by releasing SCFA, which stimulate glucagon-like peptide-1 (GLP-1) release from the large intestine, through the action of gut microbes⁽⁹³⁾. Dietary inulin-propionate ester is metabolised by gut microbes to deliver propionate to the large intestine^(94,95). Propionate acutely stimulates GLP-1 production resulting in appetite suppression and decreased energy intake⁽⁹³⁾. However, the effect on GLP-1 release is not well sustained over time, while the effect on appetite suppression is maintained⁽⁹³⁾, suggesting that other mechanisms unrelated to GLP-1 may operate⁽⁹⁶⁾. Other physical effects of dietary fibre (e.g. viscosity, gel formation) could also play a role in appetite suppression⁽⁹⁷⁾. Although the underlying mechanism of dietary fibre and appetite suppression is not fully confirmed, the collective evidence would support the use of high-fibre diets for weight control^(93–95,97,98). Fig. 3 illustrates the levels of ketones, propionate and satiety in relation to carbohydrate and dietary fibre intakes.

Opportunities for the use of low-carbohydrate diets as a treatment strategy for patients with type 2 diabetes

Controlling blood glucose within a desirable range, evaluated via measurement of HbA1c, is a primary aim for T2D management^(99,100). LCD have been postulated to have physiological benefits over higher carbohydrate diets for HbA1c reduction. A lower postprandial glucose excursion would be expected after LCD, compared to higher carbohydrate diets if they present greater glycaemic index or glycaemic loads^(66,101). A reduced postprandial excursion should lead to a better overall glucose control and lower HbA1c. Recent clinical guidelines recommend individualised nutrition therapy for people with T2D, and allow flexibility of carbohydrate intake to suit personal preferences and metabolic goals^(99,100). However, the role of LCD in T2D remains

unclear and often yield mixed results^(102–104). This is likely to be influenced by the level of energy restriction, and protein/fat composition of the diets.

Randomised controlled trials and meta-analyses evidence of low-carbohydrate diets for blood glucose control

Meta-analyses of LCD in patients with T2D have shown little greater reductions in HbA1c compared to higher-carbohydrate diets, by 0.17 to 0.34% over a short-term period up to 6 months with evidence grades ranging from very-low to moderate certainty^(102–104). Notably, results from RCT with <6 months duration showed that a lower carbohydrate intake was associated with a greater extent HbA1c reduction ($r -0.8$, $P < 0.01$)⁽¹⁰⁴⁾, this could be explained by a greater weight loss following LCD within 6 months duration^(4,102,103). However, there is no difference in HbA1c reduction between the two diets at 12 months or longer^(102–104). The definitions of LCD in those meta-analyses were <45% energy from carbohydrates, which departs from more conservative definitions. More importantly, the difference in HbA1c reduction between the two diets is of unclear clinical importance, with a majority of RCT included in those meta-analyses with high risk of bias^(102,103).

Randomised controlled trials evidence for type 2 diabetes remission

There have been debates on the definitions of remission of T2D^(105,106). While there is no consensus on the remission criteria, it is obvious that blood sugar, both HbA1c and fasting blood glucose, should be below the diagnostic threshold for diagnosis of T2D. To date, there is no RCT to study the effect of LCD on T2D remission, and clinical trials aiming at T2D remission outcome were also limited with an unclear report on the remission rate and criteria^(69,88). A single-arm longitudinal study of a Low-Carb Program in patients with T2D reported a 1-year result that 26% of patients ($n 195/743$) had HbA1c below 6.5%, with either metformin or no prescribed diabetes medication⁽⁶⁹⁾. Another non-RCT (Virta Health study) also reported that 25.5% ($n 52/204$) participants in the LCD group (carbohydrate <30 g/d, with behavioural therapy and frequent follow-up) had HbA1c below 6.5% without prescribed diabetes medication at 1 year of intervention⁽⁸⁸⁾.

Weight loss masking the effect of low-carbohydrate diets on blood glucose improvement and type 2 diabetes remission

HbA1c reduction and T2D remission following LCD have been largely confounded by weight loss^(69,88,102–104,107), leaving considerable doubt over the benefit for HbA1c which can be attributed to carbohydrate quantity *per se*. Most evidence featuring in meta-analyses comparing the impact of LCD and LFD on HbA1c was weight loss trials^(69,88,102–104). Similarly, the Virta Health study showed a reduction in HbA1c, from 7.6 to 6.3%, along with a mean weight loss of 14 kg in patients with T2D⁽⁸⁸⁾.

Evidence of LCD in non-weight loss trials is limited. A crossover RCT of a low-carbohydrate, high-protein (LCHP) diet (30% energy carbohydrate, 30% energy protein) *v.* an isoenergetic conventional diabetes diet (50% energy carbohydrate, 17% energy protein) reported a greater reduction in HbA1c in the LCHP group (-0.6 (SD 0.1)%) compared to the conventional diabetes group (-0.1 (SD 0.1)%; $P < 0.001$)⁽¹⁰⁸⁾. This study, however, is limited by a small sample size ($n = 28$), short duration (6 weeks for each diet) and no washout period, which could not exclude carryover effect. More importantly, greater weight loss was reported in the LCHP group (-1.4 kg) than the conventional diabetes group (-0.8 kg; $P = 0.07$)⁽¹⁰⁸⁾. Another crossover RCT of LCHP diet *v.* LFD ($n = 8$; 5 weeks) also showed a greater reduction in HbA1c following LCHP, but it is noted that there was a 2 kg weight loss during the 5-week study duration regardless of diet⁽¹⁰⁹⁾. The greater HbA1c reduction following LCHP could be attributed to the insulinotropic effect of high protein intake^(110–113). The results, therefore, need to be confirmed by larger and longer duration RCTs.

Randomised controlled trials evidence for vascular and renal function in type 2 diabetes

Long-term RCT evidence on the safety of LCD is limited. One RCT comparing very low-carbohydrate, low-saturated fat diet *v.* low-fat, low-saturated fat diets in patients with T2D and no pre-existing kidney disease reported that no difference was found in vascular function determined by flow mediated dilatation that might be explained by these two diets had a similar level of SFA⁽¹¹⁴⁾. Regarding renal function, a meta-analysis of nine RCT of LCD and LFD for weight loss showed that a mean change in an estimated glomerular filtration rate following LCD was little greater than LFD by 0.13 ml/min per 1.73 m², with duration up to 1–2 years⁽¹¹⁵⁾.

Dietary recommendations for patients with type 2 diabetes

While there is no ideal amount of carbohydrates for patients with T2D, a guideline emphasises reduction of refined carbohydrates and added sugars, and focus on carbohydrates from vegetables, legumes, fruit, dairy (milk and yoghurt) and whole grains, in order to achieve healthful eating patterns with a variety of nutrient-dense foods⁽⁹⁹⁾. If patients prefer LCD, this approach should be only used for a short-term, up to 3–4 months, due to limited evidence on long-term benefits and harms of LCD⁽⁹⁹⁾.

Challenges associated with the use of low-carbohydrate diets

Low-carbohydrate diets and micronutrients

While weight is often the main outcome, nutritional quality of all diets should be a key primary concern. As key characteristic of LCD, avoidance of whole grains, fruit and starchy vegetables could reduce

vitamins, minerals as well as plant bioactives (which play a role in the modulation of glycaemic stress^(116,117), relevant to T2D pathophysiology). The negative impact of LCD on micronutrients has often been neglected. Our systematic review⁽¹¹⁸⁾ found seven RCT^(73,119–124), two non-controlled trials^(125,126) and one cross-sectional study⁽¹²⁷⁾ reporting rather consistent reductions in thiamine (vitamin B₁), folate, vitamin C, magnesium, calcium, iron and iodine intakes⁽¹¹⁸⁾. Although there is no definitive guidance for supplementation during LCD, only one study provided supplementation to participants⁽¹²⁶⁾. Most of the studies included did not report on supplements used in their studies⁽¹¹⁸⁾. It is therefore difficult to assess whether inadequate micronutrient intakes have been topped-up by supplementation⁽¹¹⁸⁾.

This could have clinical consequences. For example, severe thiamine deficiency and beriberi are well-recognised with prolonged extreme LCD^(128,129). Inadequate intakes of folate and iodine in women of child-bearing age could increase the risk of poor fetal outcomes⁽¹³⁰⁾. Gardner *et al.* showed that individuals on the Atkins diet had lower intake of thiamine and magnesium over 8 weeks⁽¹²⁰⁾. Unfortunately, there have been case reports of thiamine deficiency from following a LCD. Bilateral optic neuropathy was reported in two patients who followed a prolonged carbohydrate-restricted diet⁽¹²⁸⁾. Another case of Wernicke's encephalopathy and cardiac beriberi was reported in a patient with obesity who restricted breads and pasta from his diet⁽¹²⁹⁾.

Low-carbohydrate diets and LDL-cholesterol

Lipid disturbance is commonly seen in individuals with overweight and obesity, including those with T2D, who are at high risk of atherosclerotic CVD (ASCVD). High TAG and low HDL-cholesterol are risk factors of ASCVD, while high LDL-cholesterol is a main culprit of ASCVD, depositing in an arterial wall, initiating plaque formation and progression of ASCVD^(131,132). There has long been a concern about increasing LDL-cholesterol following LCD, albeit balanced by decreasing the TAG level⁽⁴⁾.

Evidence from weight loss trials showed that LCD increased LDL-cholesterol to a greater extent compared to LFD (by 0.1 to 0.4 mm, or 4 to 16 mg/dl) over 6 to 24 months intervention^(38–41,71,133). The lower carbohydrate component in the diet may be associated with a greater increment in the LDL-cholesterol level, as seen in a cohort of patients with T2D following ketogenic diets (<30 g/d of carbohydrate) that LDL-cholesterol increased by 10% after 1 year of the diet⁽⁸⁸⁾. In non-weight loss studies^(44,89,134), low-carbohydrate, high-fat, high saturated fat diets (18–25% energy saturated fat) for 3–4 weeks, showed 17–21% increment in LDL-cholesterol from baseline, including increments in small and medium LDL particles^(44,89).

Most importantly, there were two case reports of acute coronary syndrome in patients following the Atkins diet. A 51-year-old man, healthy, physically active, no previous heart disease, diabetes, hypertension or



dyslipidaemia developed a marked change in LDL-cholesterol, from 2.2 mM (85 mg/dl) at 6 months prior to the Atkins diet to 4 mM (154 mg/dl) at 1 month after the diet, BMI 21.8 kg/m², despite a 3 kg weight loss. The patient remained on this diet until 29 months later when he experienced exertional chest pain, and his cardiac catheterisation demonstrated a severe stenosis of the left anterior descending artery⁽¹³⁵⁾. Another case report was a 41-year-old man, who had no ASCVD risks and no family history of premature coronary artery disease. His BMI was 19.5 kg/m². The patient adhered to the Atkins diet for 6 years with repeated cycles each year. His blood lipids, apolipoprotein A and homocysteine levels were within normal limits. He presented with acute chest pain in which the investigation showed an acute myocardial infarction⁽¹³⁶⁾.

Low-carbohydrate diets and ketoacidosis

Ketosis is associated with, and largely causes, dangerous acidosis (ketoacidosis) in poorly treated insulin-deficient type 1 diabetes. Apart from micronutrient inadequacies and increased LDL-cholesterol, ketosis usually develops in individuals following LCD⁽⁸⁸⁾. Although there is no severe ketoacidosis reported in clinical trials, there is a case report of ketoacidosis in a non-diabetic lactating woman following a ketogenic diet with <20 g/d carbohydrate. The patient developed nausea and vomiting after 10 d of the diet. Serum pH was 7.2 indicating acidosis, with blood ketones of 7.1 mM (reference <0.5 mM). The authors hypothesised that lactation could aggravate or trigger ketoacidosis: during lactation, women require increased energy intake to meet the high demand of substrate to produce milk. Fat, whether stored or dietary, is the primary resource of energy during a ketogenic diet, and thus responsible for ketoacidosis⁽¹³⁷⁾.

Long-term epidemiological evidence on low-carbohydrate diets, type 2 diabetes, cardiovascular risks and mortality

Intervention studies comparing LCD and LFD have shown little or no difference on weight change over 1–2 years, but do not have long enough follow-up to study the clinical outcomes such as incident T2D, CVD and mortality or long-term safety.

Low-carbohydrate diets, HbA1c level and incident type 2 diabetes

Our cross-sectional analysis in people without known diabetes in the National Diet and Nutrition Survey in the UK showed that, although few people (*n* 8 or 0.24 % of the overall sample) met the conservative definition of LCD (<26 % energy), both lower carbohydrate intake (per 5 % energy band) and LCD pattern (according to LCD adherence score), were associated with higher HbA1c (+0.16 mmol/mol, *P* = 0.012, per 5 % energy decrease in carbohydrate; +0.10 mmol/mol, *P* = 0.001, per 2-point increase in LCD adherence score)⁽¹³⁸⁾. The National Diet and Nutrition Survey used food diaries for the estimation of dietary intakes, which are more

accurate and less reliant on memories compared to the FFQ. While the study design does not inform cause and effect, the findings are to some extent in line with longitudinal studies^(139,140). This evidence indicates that it is unlikely that consuming lower carbohydrate content *per se* could lower the HbA1c level. Other mechanisms (e.g. oxidative stress, peripheral insulin resistance) could contribute to HbA1c elevation, as high oxidative stress can enhance protein glycation without hyperglycaemia⁽¹⁴¹⁾.

When looking at incident T2D and LCD, the most recent cohort study in Australian women showed a 27 % higher risk of T2D with LCD (comparing extreme quartiles, with absolute risk increase of about 3 %), although the relative risk (RR) was attenuated to 10 % after adjustment for BMI⁽¹⁴²⁾. A meta-analysis of eleven prospective cohort studies showed that different regions had different outcomes⁽¹⁴³⁾. In Europe^(144–147), LCD increased the T2D risk by 12 % (pooled relative risk (RR) 1.12; 95 % CI 1.04, 1.20), whereas in Japan⁽¹⁴⁸⁾ and China⁽¹⁴⁹⁾, LCD decreased the T2D risk by 20 % (pooled RR 0.80; 95 % CI 0.70, 0.90)⁽¹⁴³⁾. The pooled result in Asian countries was explained by white rice as a key food source of (refined) carbohydrate, a major component in Japanese and Chinese diets^(148,149). A study showed that substituting white rice with brown rice or wholegrain could result in T2D risk reduction by 16 and 36 % respectively⁽¹⁵⁰⁾.

Sources of protein and fat in replacing carbohydrate also contributed to T2D risk. LCD with high animal protein and fat was associated with a 37 % increase in T2D risk in men (95 % CI 1.2, 1.58; *P*-trend <0.01)⁽¹³⁹⁾, and a 40 % increase in T2D risk in women with history of gestational diabetes (95 % CI 1.06, 1.84; *P*-trend = 0.004)⁽¹⁵¹⁾. Conversely, LCD with vegetable protein and fat was associated with a 18 % T2D risk reduction in women (95 % CI 0.71, 0.94; *P*-trend = 0.001)⁽¹⁵²⁾. Contrary findings between men and women could be explained by sex differences in T2D susceptibility⁽¹⁵³⁾. Pre-menopausal women are less susceptible to T2D than men, partly explained by the difference in sex steroid hormones⁽¹⁵³⁾. Endogenous oestrogen plays a protective role in various metabolic regulations including insulin secretion and sensitivity, although the underlying mechanism has yet to be explored⁽¹⁵³⁾. Women have higher capability for lipid utilisation, favouring subcutaneous adipose tissue as an energy storage, preventing them from ectopic fat accumulation⁽¹⁵³⁾.

Low-carbohydrate diets and CVD

In the prospective cohort Nurses Health Study of 82 802 women, diets were assessed by a validated FFQ and a calculated 'LCD score' (higher scores representing higher intakes of fat and protein, and lower intake of carbohydrate). During the 20 years follow-up, a higher LCD score (10th decile *v.* 1st decile) was associated with a 29 % increased risk of CHD (age-adjusted RR 1.29; 95 % CI 1.04, 1.60). After adjustment for BMI, smoking status, physical activity, history of diabetes and hypertension, the adjusted RR for CHD was attenuated to 0.94 (95 % CI 0.76, 1.18, *P* for trend 0.19). Interestingly, when analysing the LCD score based on vegetable

protein and vegetable fat, the adjusted RR of CHD was 0.70 (95% CI 0.56, 0.88; *P*-trend 0.002) whereas when animal protein and animal fat were chosen, the adjusted RR was 0.94 (95% CI 0.74, 1.19; *P*-trend 0.52)⁽¹⁵⁴⁾. When using a composite outcome of cardiovascular events (IHD, ischemic stroke, haemorrhagic stroke, subarachnoid haemorrhage and peripheral arterial disease), a large cohort study of 43 396 Swedish women reported that every two units greater in the LCHP diet score was associated with a 5% increase in the incidence of cardiovascular events (incidence rate ratio 1.05; 95% CI 1.02, 1.08)⁽¹⁵⁵⁾.

LCD are also associated with increased risk of incident atrial fibrillation⁽¹⁵⁶⁾. Findings from a large prospective community-based cohort study (Atherosclerosis Risk in Communities Study) showed that every 9.4% higher in carbohydrate intake as percentage of energy (1-standard deviation) was associated with reduced risk of incident atrial fibrillation by 18% (adjusted hazard ratio 0.82; 95% CI 0.72, 0.94), while there was no association found between animal and plant sources of protein and fat and incident atrial fibrillation⁽¹⁵⁶⁾. These contrasting findings highlight the need to pay greater attention to the foods (and nutrients) replacing carbohydrates in LCD.

Low-carbohydrate diets and mortality

Several prospective cohort studies and their meta-analyses showed consistent findings that the LCD pattern was associated with an increased risk of all-cause mortality and cardiovascular mortality^(157–163). The Atherosclerosis Risk in Communities Study found a U-shaped association between carbohydrate intake (% energy) and all-cause mortality, with the lowest mortality risk at 50–55% energy carbohydrate. The authors also conducted the meta-analysis for carbohydrate and mortality^(162–164). Compared to moderate carbohydrate intake (about 50% energy), low carbohydrate intake (<40% energy) was associated with a 20% increased risk of all-cause mortality (pooled hazard ratio 1.2; 95% CI 1.09, 1.32; *P*<0.0001), and high carbohydrate intake (>70% energy) was also associated with a 23% increased risk of all-cause mortality (pooled hazard ratio 1.23; 95% CI 1.11, 1.36; *P*<0.0001)⁽¹⁶³⁾. The meta-analysis also showed that mortality increased by 18% when replacing carbohydrate with animal-sourced fat and protein, and decreased by 18% when replacing carbohydrate with plant-sourced fat and protein⁽¹⁶³⁾. Another population-based cohort study also showed a 22% increased risk of all-cause mortality, a 13% increased risk of ASCVD mortality and an 8% increased risk of cancer death in associations with LCD pattern (comparing between extreme quartiles, adjusted for BMI)⁽⁵⁾.

Analysis of the combined databases of the Nurses Health Study and the Health Professional Follow-Up Study was performed in the population of post-myocardial infarction survivors⁽¹⁶⁵⁾. Those in the highest quintile of the LCD score from animal-sourced protein and fat had a 33% higher risk of all-cause mortality (95% CI 1.06, 1.65) and a 51% increased risk of cardiovascular mortality (95% CI 1.09, 2.07) than those in the

lowest quintile⁽¹⁶⁵⁾. Interestingly, individuals who changed their diet from pre- to post-myocardial infarction towards the LCD pattern was also associated with higher all-cause and cardiovascular mortality by 30 and 53% respectively.⁽¹⁶⁵⁾

Real world data on the use of low-carbohydrate diets

Evidence documenting the use of LCD outside clinical trials remains scarce. In the UK, an estimated three-million people have tried LCD, accounting for 7–10% of respondents in a media poll⁽⁴⁹⁾, similar to a finding of 7% from a population-based survey in Finland⁽¹⁶⁶⁾, while it was up to 17% in a nationally representative samples from the Health Information National Trends Survey in the USA⁽³⁾. A survey of individuals following LCD (in the Active Low-Carber Forum, an online support group for LCD in the USA) reported that Atkins-style diets ranked top of LCD used, accounting for 74% of reports⁽¹⁶⁷⁾. Two-third of respondents had lost 30 lbs in weight, or more⁽¹⁶⁷⁾. Avoiding sugar (94%) and avoiding starch (84%) were important factors for weight loss plan, while only 12% of respondents thought that ‘decreasing fat’ was an important factor⁽¹⁶⁷⁾.

There is limited evidence for the use of LCD in clinical practice. Dr Unwin *et al.* reported a case series of nineteen patients with T2D and pre-diabetes who participated in a LCD programme from one general practice⁽⁷⁰⁾. The LCD advice was to reduce all starchy carbohydrate foods (e.g. breads, pasta, rice), tropical fruit and vegetable oils, while promoting consumptions of green vegetables, berries, meat, eggs, fish, olive oil, coconut oil and butter. Patients were also advised to consume processed meat such as sausages, bacon, ham, in moderation. One patient withdrew at the initial stage for personal reason. Of eighteen patients, mean weight loss was 8.6 (SD 4.2) kg (*P*<0.0001), and HbA1c dropped significantly from 51 (SD 14) to 40 (SD 4) mmol/mol (*P*<0.001) over 8 months⁽⁷⁰⁾. Although this report was of small sample size with no control diet, it emphasised that LCD can be effective for weight loss and glucose control, and can be implemented in clinical practice. Long-term data of LCD in patients with T2D in primary care has the potential to depict both benefits and risks on hard clinical outcomes especially CVD events, renal adverse effects and even mortality. The role of the health-care practitioner as a source of support is also an important consideration in the context of this work.

Real-world data on dietary intakes in self-reported LCD followers are also limited^(127,168). A recent cross-sectional study from Iceland with fifty-four self-reported LCD followers (80% overweight and 60% with elevated LDL-cholesterol level) demonstrated further insight into nutrient intakes⁽¹²⁷⁾. Median intake of carbohydrate was very low (only 8% energy) while median fat intake was very high at 68% energy, with 25% energy from SFA. Consumption of whole grain was only 5 g/d and fibre only 11 g/d. Vegetable intake was of 170 g/d compared to 120 g/d of general population; this shows that vegetable intake is an important source of fibre in the




Fig. 4. (Colour online) Opportunities and challenges for low-carbohydrate diets (LCD) in type 2 diabetes management and prevention. The solid line indicates extensive and strong evidence. The dashed line indicates limited evidence. (+) indicates positive effect. (–) indicates negative effect. (?) indicates no sufficient evidence. T2D, type 2 diabetes.

context of LCD, requiring further emphasis (beyond the simple 5-a-day message) when carbohydrate-rich foods are limited or excluded. Red meat intake was 130 g/d, nearly double the intake of the general population in Iceland. Approximately half of the participants had intakes of vitamin A, thiamine, folate, vitamin C, calcium, iron and magnesium lower than recommendations. In contrast, 75% of participants consumed greater sodium than recommended (2400 mg daily)⁽¹²⁷⁾.

As such, healthfulness of LCD is highly dependent on choices of the foods to restrict but also foods to include and promote. As practiced, LCD may not be a healthful, nutritionally-replete dietary approach, unless great care is taken to balance intakes. In USA, LCD followers had a healthy eating index score lower than those with higher carbohydrate diets (58.2 v. 70.4, $P = 0.012$)⁽¹⁶⁸⁾. Only half of LCD followers had support from their doctors, and two-thirds valued information from online supporting websites instead of government websites/publications⁽¹⁶⁷⁾. Our own work is currently seeking to establish a clearer picture of such practice (C Churuangasuk, MEJ Lean and E Combet, unpublished results). Fig. 4 summarises the opportunities and challenges presented by LCD in T2D management and prevention.

Limitations of current research

The well-known limitation of the RCT of LCD is the absence of evidence for long-term effectiveness on hard clinical outcomes such as incident T2D, cardiovascular events and mortality, instead of weight loss. Regarding T2D management, remission should be a primary aim for T2D treatment especially in early T2D, and high quality RCT of LCD aiming at T2D remission in comparison with other weight loss diets or routine care are needed.

RCT and epidemiological evidence showed that the selection of food choices/sources of protein and fat

could have different effects on health, but limited RCT on the effect of food choices/sources of protein and fat in replacing carbohydrate have been conducted^(45,46). It is possible to design a healthful LCD with a complete micronutrient profile and no detrimental effect on LDL-cholesterol^(45,46,169), but this may require close supervision by dietitians in collaboration with other health care professionals.

The ongoing debate on the usefulness of FFQ as a dietary assessment tool in epidemiological studies has highlighted the pitfalls associated with poorer accuracy of nutrient intake estimation and reliance on memory for recall. While FFQ are practical in the context of large sample sizes (e.g. population-based study) and to rank dietary data, carbohydrate intake reports generated via this method should be evaluated carefully. While the epidemiological evidence to date shows detrimental effects of LCD on health, the amount of carbohydrate consumed is usually higher than intakes relevant to individuals following (very) low carbohydrate intake, <20–30% energy. Real-world data in self-reported low-carbohydrate dieters may help better elucidate the relationship between LCD, dietary habits and long-term health status.

Conclusions

RCT clearly show the efficacy of LCD for weight loss in people with obesity and/or T2D, leading to glycaemic improvement. Their efficacy, however, is little different from that of higher carbohydrate diets or other weight loss diets with less drastic restriction of whole food groups. Many studies show only short-term benefit when compared to higher carbohydrate diets. LCD may be preferred by some people, and have value at least for short-term results, but may potentially lead to micronutrient deficiencies and increased LDL-cholesterol, and there are longer-term risks of T2D and

CVD. Ensuring dietary micronutrient adequacy through food fortification or supplementation should be considered for all who wish to pursue or prescribe long-term LCD. Food choices in replacement of the carbohydrate source may alleviate the negative effects of LCD, but evidence on this topic remains limited. Evidence is lacking over whether the main energy source during LCD should be fat or protein. Long-term, high-quality RCT of LCD with different food sources between animal and plants, aiming for hard clinical endpoints instead of weight loss are difficult to conduct, but needed to generate reliable advice.

Acknowledgements

The authors would like to acknowledge Prince of Songkla University, Faculty of Medicine for their support.

Financial Support

C. C. is in receipt of a scholarship from Prince of Songkla University, Faculty of Medicine, Thailand. Prince of Songkla University, Faculty of Medicine had no role in the design, analysis or writing of this article.

Conflicts of Interest

M. E. J. L. reports departmental research funding from Diabetes UK and Novo Nordisk, and personal fees for consultancy, advisory boards and lecturing from Novo Nordisk, Eli Lilly, Roche and Sanofi. EC reports current funding from Filippo Berio.

Authorship

C. C. gathered and critically appraised the literature and drafted the manuscript. E. C. and M. E. J. L. reviewed and contributed to the manuscript.

References

1. Feinman RD, Pogozelski WK, Astrup A *et al.* (2015) Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base. *Nutrition* **31**, 1–13.
2. Feinmann J (2017) Practices should be able to keep money saved from putting patients on low carbohydrate diet, GP says. *Br Med J* **357**, j1677.
3. Finney Rutten LJ, Lazarus Yaroch A, Colon-Ramos U *et al.* (2008) Awareness, use, and perceptions of low-carbohydrate diets. *Prev Chronic Dis* **5**, A130.
4. Churuangasuk C, Kherouf M, Combet E *et al.* (2018) Low-carbohydrate diets for overweight and obesity: a systematic review of the systematic reviews. *Obes Rev* **19**, 1700–1718.
5. Mazidi M, Katsiki N, Mikhailidis DP *et al.* (2019) Lower carbohydrate diets and all-cause and cause-specific mortality: a population-based cohort study and pooling of prospective studies. *Eur Heart J* **40**, 2870–2879.
6. Dyson P, McArdle P, Mellor D *et al.* (2019) James Lind Alliance research priorities: what role do carbohydrates, fats and proteins have in the management of Type 2 diabetes, and are there risks and benefits associated with particular approaches? *Diabet Med* **36**, 287–296.
7. Brouns F (2018) Overweight and diabetes prevention: is a low-carbohydrate-high-fat diet recommendable? *Eur J Nutr* **57**, 1301–1312.
8. World Health Organization (2016) *Overweight and Obesity*. <http://www.who.int/mediacentre/factsheets/fs311/en/> (accessed May 2017).
9. World Health Organization (2018) *Diabetes Fact sheets*. <https://www.who.int/news-room/fact-sheets/detail/diabetes> (accessed October 2019).
10. Colditz GA, Willett WC, Stampfer MJ *et al.* (1990) Weight as a risk factor for clinical diabetes in women. *Am J Epidemiol* **132**, 501–513.
11. Rana JS, Li TY, Manson JE *et al.* (2007) Adiposity compared with physical inactivity and risk of type 2 diabetes in women. *Diabetes Care* **30**, 53–58.
12. Taylor R, Al-Mrabeh A, Zhyzhneuskaya S *et al.* (2018) Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for beta cell recovery. *Cell Metab* **28**, 547–556. e543.
13. Dunkley AJ, Bodicoat DH, Greaves CJ *et al.* (2014) Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis. *Diabetes Care* **37**, 922–933.
14. Howard BV, Aragaki AK, Tinker LF *et al.* (2018) A low-fat dietary pattern and diabetes: a secondary analysis from the women's health initiative dietary modification trial. *Diabetes Care* **41**, 680–687.
15. Knowler WC, Barrett-Connor E, Fowler SE *et al.* (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* **346**, 393–403.
16. Tuomilehto J, Lindstrom J, Eriksson JG *et al.* (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* **344**, 1343–1350.
17. Lean ME, Leslie WS, Barnes AC *et al.* (2018) Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. *Lancet* **391**, 541–551.
18. Lean MEJ, Leslie WS, Barnes AC *et al.* (2019) Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. *Lancet Diabetes Endocrinol.* **7**, 344–355.
19. Brownson RC, Boehmer TK & Luke DA (2005) Declining rates of physical activity in the United States: what are the contributors? *Annu Rev Public Health* **26**, 421–443.
20. Braam LA, Ocke MC, Bueno-de-Mesquita HB *et al.* (1998) Determinants of obesity-related underreporting of energy intake. *Am J Epidemiol* **147**, 1081–1086.
21. Lara JJ, Scott JA & Lean ME (2004) Intentional misreporting of food consumption and its relationship with body mass index and psychological scores in women. *J Hum Nutr Diet* **17**, 209–218.
22. Hall KD (2018) Did the food environment cause the obesity epidemic? *Obesity* **26**, 11–13.



23. Putnam J, Allshouse J & Kantor LS (2002) U.S. per capita food supply trends: more calories, refined carbohydrates, and fats. *Food Review/National Food Review* **25**, 2–15.
24. Sturm R & An R (2014) Obesity and economic environments. *CA Cancer J Clin* **64**, 337–350.
25. Vandevijvere S, Chow CC, Hall KD *et al.* (2015) Increased food energy supply as a major driver of the obesity epidemic: a global analysis. *Bull World Health Organ* **93**, 446–456.
26. Bates B, Lennox A, Prentice A *et al.* (2014) National Diet and Nutrition Survey Results from Years 1, 2, 3 and 4 (combined) of the Rolling Programme (2008/2009–2011/2012). (accessed October 2018).
27. The Scientific Advisory Committee on Nutrition (2015) SACN Carbohydrates and Health Report. <https://www.gov.uk/government/publications/sacn-carbohydrates-and-health-report> (accessed December 2019).
28. Lean MEJ & Combet E (2017) *Barasi's Human Nutrition: A Health Perspective*, 3rd ed. Florida: CRC Press, Taylor & Francis Group.
29. Reynolds A, Mann J, Cummings J *et al.* (2019) Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. *Lancet* **393**, 434–445.
30. Hervik AK & Svihus B (2019) The role of fiber in energy balance. *J Nutr Metab* **2019**, 4983657.
31. Kristensen M & Jensen MG (2011) Dietary fibres in the regulation of appetite and food intake. Importance of viscosity. *Appetite* **56**, 65–70.
32. Te Morenga L, Mallard S & Mann J (2012) Dietary sugars and body weight: systematic review and meta-analyses of randomised controlled trials and cohort studies. *Br Med J* **346**, e7492.
33. Martinez Steele E, Baraldi LG, Louzada ML *et al.* (2016) Ultra-processed foods and added sugars in the US diet: evidence from a nationally representative cross-sectional study. *BMJ Open* **6**, e009892.
34. Rauber F, Louzada M, Martinez Steele E *et al.* (2019) Ultra-processed foods and excessive free sugar intake in the UK: a nationally representative cross-sectional study. *BMJ Open* **9**, e027546.
35. Poti JM, Braga B & Qin B (2017) Ultra-processed food intake and obesity: what really matters for health-processing or nutrient content? *Curr Obes Rep* **6**, 420–431.
36. Hall KD, Ayuketah A, Brychta R *et al.* (2019) Ultra-processed diets cause excess calorie intake and weight gain: an inpatient randomized controlled trial of ad libitum food intake. *Cell Metab* **30**, 67–77.e63.
37. Atkins RC (2003) *Dr Atkins New Diet Revolution*. London: Vermilion.
38. Mansoor N, Vinknes KJ, Veierod MB *et al.* (2016) Effects of low-carbohydrate diets v. low-fat diets on body weight and cardiovascular risk factors: a meta-analysis of randomised controlled trials. *Br J Nutr* **115**, 466–479.
39. Sackner-Bernstein J, Kanter D & Kaul S (2015) Dietary intervention for overweight and obese adults: comparison of low-carbohydrate and low-fat diets. A meta-analysis. *PLoS One* **10**, e0139817.
40. Bueno NB, de Melo IS, de Oliveira SL *et al.* (2013) Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. *Br J Nutr* **110**, 1178–1187.
41. Hession M, Rolland C, Kulkarni U *et al.* (2009) Systematic review of randomized controlled trials of low-carbohydrate vs. low-fat/low-calorie diets in the management of obesity and its comorbidities. *Obes Rev* **10**, 36–50.
42. Gardner CD, Trepanowski JF, Del Gobbo LC *et al.* (2018) Effect of low-fat vs low-carbohydrate diet on 12-month weight loss in overweight adults and the association with genotype pattern or insulin secretion: the DIETFITS randomized clinical trial. *JAMA* **319**, 667–679.
43. Frigolet ME, Ramos Barragan VE & Tamez Gonzalez M (2011) Low-carbohydrate diets: a matter of love or hate. *Ann Nutr Metab* **58**, 320–334.
44. Chiu S, Williams PT & Krauss RM (2017) Effects of a very high saturated fat diet on LDL particles in adults with atherogenic dyslipidemia: a randomized controlled trial. *PLoS One* **12**, e0170664.
45. Tay J, Luscombe-Marsh ND, Thompson CH *et al.* (2014) A very low-carbohydrate, low-saturated fat diet for type 2 diabetes management: a randomized trial. *Diabetes Care* **37**, 2909–2918.
46. Jenkins DJ, Wong JM, Kendall CW *et al.* (2009) The effect of a plant-based low-carbohydrate ('Eco-Atkins') diet on body weight and blood lipid concentrations in hyperlipidemic subjects. *Arch Intern Med* **169**, 1046–1054.
47. Johnston BC, Kanters S, Bandayrel K *et al.* (2014) Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. *JAMA* **312**, 923–933.
48. Astrup A, Meinert Larsen T & Harper A (2004) Atkins and other low-carbohydrate diets: hoax or an effective tool for weight loss? *Lancet* **364**, 897–899.
49. BBC (2003) Three million follow Atkins diet. <http://news.bbc.co.uk/1/hi/health/3197627.stm> (accessed May 2017).
50. Barford V (2013) Atkins and the never-ending battle over carbs. In *BBC News Magazine*. <http://www.bbc.co.uk/news/magazine-22145709> (accessed May 2017).
51. Ludwig DS & Ebbeling CB (2018) The carbohydrate-insulin model of obesity: beyond 'Calories In, Calories Out'. *JAMA Intern Med* **178**, 1098–1103.
52. Krebs JD, Bell D, Hall R *et al.* (2013) Improvements in glucose metabolism and insulin sensitivity with a low-carbohydrate diet in obese patients with type 2 diabetes. *J Am Coll Nutr* **32**, 11–17.
53. Kirk E, Reeds DN, Finck BN *et al.* (2009) Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. *Gastroenterology* **136**, 1552–1560.
54. Numao S, Kawano H, Endo N *et al.* (2012) Short-term low carbohydrate/high-fat diet intake increases postprandial plasma glucose and glucagon-like peptide-1 levels during an oral glucose tolerance test in healthy men. *Eur J Clin Nutr* **66**, 926–931.
55. Johnson NA, Stannard SR, Rowlands DS *et al.* (2006) Effect of short-term starvation versus high-fat diet on intramyocellular triglyceride accumulation and insulin resistance in physically fit men. *Exp Physiol* **91**, 693–703.
56. Bachmann OP, Dahl DB, Brechtel K *et al.* (2001) Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans. *Diabetes* **50**, 2579–2584.
57. Stettler R, Ith M, Acheson KJ *et al.* (2005) Interaction between dietary lipids and physical inactivity on insulin sensitivity and on intramyocellular lipids in healthy men. *Diabetes Care* **28**, 1404–1409.
58. Branis NM, Etesami M, Walker RW *et al.* (2015) Effect of a 1-week, eucaloric, moderately high-fat diet on peripheral insulin sensitivity in healthy premenopausal women. *BMJ Open Diabetes Res Care* **3**, e000100.

59. Garg A, Grundy SM & Unger RH (1992) Comparison of effects of high and low carbohydrate diets on plasma lipoproteins and insulin sensitivity in patients with mild NIDDM. *Diabetes* **41**, 1278–1285.
60. Summers LK, Fielding BA, Bradshaw HA *et al.* (2002) Substituting dietary saturated fat with polyunsaturated fat changes abdominal fat distribution and improves insulin sensitivity. *Diabetologia* **45**, 369–377.
61. Lamont BJ, Waters MF & Andrikopoulos S (2016) A low-carbohydrate high-fat diet increases weight gain and does not improve glucose tolerance, insulin secretion or beta-cell mass in NZO mice. *Nutr. Diabetes* **6**, e194.
62. Ellenbroek JH, van Dijck L, Tons HA *et al.* (2014) Long-term ketogenic diet causes glucose intolerance and reduced beta- and alpha-cell mass but no weight loss in mice. *Am. J. Physiol. Endocrinol. Metab.* **306**, E552–E558.
63. Banting W (1993) Letter on corpulence, addressed to the public. 1869. *Obes. Res.* **1**, 153–163.
64. O'Connor A (2019) The Keto Diet Is Popular, but Is It Good for You? In *The New York Times*. <https://www.nytimes.com/2019/08/20/well/eat/the-keto-diet-is-popular-but-is-it-good-for-you.html> (accessed November 2019).
65. Lawler M (2018) 12 Celebrities Who Can't Get Enough of the Ketogenic Diet. <https://www.everydayhealth.com/ketogenic-diet/diet-celebrities-cant-get-enough-ketogenic-diet/> (accessed November 2019).
66. Samkani A, Skytte MJ, Kandel D *et al.* (2018) A carbohydrate-reduced high-protein diet acutely decreases postprandial and diurnal glucose excursions in type 2 diabetes patients. *Br J Nutr* **119**, 910–917.
67. Santos FL, Esteves SS, da Costa Pereira A *et al.* (2012) Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors. *Obes Rev* **13**, 1048–1066.
68. Westman EC, Yancy WS, Edman JS *et al.* (2002) Effect of 6-month adherence to a very low carbohydrate diet program. *Am J Med* **113**, 30–36.
69. Saslow LR, Summers C, Aikens JE *et al.* (2018) Outcomes of a digitally delivered low-carbohydrate type 2 diabetes self-management program: 1-year results of a single-arm longitudinal study. *JMIR Diabetes* **3**, e12.
70. Unwin D & Unwin J (2014) Low carbohydrate diet to achieve weight loss and improve HbA1c in type 2 diabetes and pre-diabetes: experience from one general practice. *Practical Diabetes* **31**, 76–79.
71. Nordmann AJ, Nordmann A, Briel M *et al.* (2006) Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. *Arch Intern Med* **166**, 285–293.
72. Samaha FF, Iqbal N, Seshadri P *et al.* (2003) A low-carbohydrate as compared with a low-fat diet in severe obesity. *N Engl J Med* **348**, 2074–2081.
73. Brehm BJ, Seeley RJ, Daniels SR *et al.* (2003) A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women. *J Clin Endocrinol Metab* **88**, 1617–1623.
74. Naude CE, Schoonees A, Senekal M *et al.* (2014) Low carbohydrate versus isoenergetic balanced diets for reducing weight and cardiovascular risk: a systematic review and meta-analysis. *PLoS One* **9**, e100652.
75. Boden G, Sargrad K, Homko C *et al.* (2005) Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes. *Ann Intern Med* **142**, 403–411.
76. Alhassan S, Kim S, Bersamin A *et al.* (2008) Dietary adherence and weight loss success among overweight women: results from the A TO Z weight loss study. *Int J Obes (Lond)* **32**, 985–991.
77. Pagoto SL & Appelhans BM (2013) A call for an end to the diet debates. *JAMA* **310**, 687–688.
78. Shea BJ, Reeves BC, Wells G *et al.* (2017) AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *Br Med J* **358**, j4008.
79. Hall KD & Guo J (2017) Obesity energetics: body weight regulation and the effects of diet composition. *Gastroenterology* **152**, 1718–1727.e1713.
80. Ali HI, Jarrar AH, El Sadig M *et al.* (2013) Diet and carbohydrate food knowledge of multi-ethnic women: a comparative analysis of pregnant women with and without gestational diabetes mellitus. *PLoS One* **8**, e73486.
81. Rampersaud GC, Kim H, Gao Z *et al.* (2014) Knowledge, perceptions, and behaviors of adults concerning nonalcoholic beverages suggest some lack of comprehension related to sugars. *Nutr Res* **34**, 134–142.
82. Gibson SA (1996) Are high-fat, high-sugar foods and diets conducive to obesity? *Int J Food Sci Nutr* **47**, 405–415.
83. Leidy HJ, Tang M, Armstrong CL *et al.* (2011) The effects of consuming frequent, higher protein meals on appetite and satiety during weight loss in overweight/obese men. *Obesity* **19**, 818–824.
84. Yang D, Liu Z, Yang H *et al.* (2014) Acute effects of high-protein versus normal-protein isocaloric meals on satiety and ghrelin. *Eur J Nutr* **53**, 493–500.
85. Hu T, Yao L, Reynolds K *et al.* (2016) The effects of a low-carbohydrate diet on appetite: a randomized controlled trial. *Nutr. Metab. Cardiovasc. Dis.* **26**, 476–488.
86. Johnstone AM, Horgan GW, Murison SD *et al.* (2008) Effects of a high-protein ketogenic diet on hunger, appetite, and weight loss in obese men feeding ad libitum. *Am J Clin Nutr* **87**, 44–55.
87. Gibson AA, Seimon RV, Lee CM *et al.* (2015) Do ketogenic diets really suppress appetite? A systematic review and meta-analysis. *Obes Rev* **16**, 64–76.
88. Hallberg SJ, McKenzie AL, Williams PT *et al.* (2018) Effectiveness and safety of a novel care model for the management of type 2 diabetes at 1 year: an open-label, non-randomized, controlled study. *Diabetes Ther.* **9**, 583–612.
89. Rosenbaum M, Hall KD, Guo J *et al.* (2019) Glucose and lipid homeostasis and inflammation in humans following an isocaloric ketogenic diet. *Obesity* **27**, 971–981.
90. Nymo S, Coutinho SR, Eknes PH *et al.* (2018) Investigation of the long-term sustainability of changes in appetite after weight loss. *Int J Obes* **42**, 1489–1499.
91. Nymo S, Coutinho SR, Jorgensen J *et al.* (2017) Timeline of changes in appetite during weight loss with a ketogenic diet. *Int J Obes* **41**, 1224–1231.
92. Stubbs BJ, Cox PJ, Evans RD *et al.* (2018) A ketone ester drink lowers human ghrelin and appetite. *Obesity* **26**, 269–273.
93. Chambers ES, Viardot A, Psichas A *et al.* (2015) Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. *Gut* **64**, 1744–1754.
94. Byrne CS, Chambers ES, Preston T *et al.* (2019) Effects of inulin propionate ester incorporated into palatable food products on appetite and resting energy expenditure: a randomised crossover study. *Nutrients* **11**, 861.
95. Chambers ES, Byrne CS, Morrison DJ *et al.* (2019) Dietary supplementation with inulin-propionate ester or



- inulin improves insulin sensitivity in adults with overweight and obesity with distinct effects on the gut microbiota, plasma metabolome and systemic inflammatory responses: a randomised cross-over trial. *Gut* **68**, 1430–1438.
96. Byrne CS, Chambers ES, Morrison DJ *et al.* (2015) The role of short chain fatty acids in appetite regulation and energy homeostasis. *Int J Obes* **39**, 1331–1338.
97. Poutanen KS, Dussort P, Erkner A *et al.* (2017) A review of the characteristics of dietary fibers relevant to appetite and energy intake outcomes in human intervention trials. *Am J Clin Nutr* **106**, 747–754.
98. Zhu XZ, Jia CC, Meng XY *et al.* (2018) Synthesis, characterization of inulin propionate ester, and evaluation of its in vitro effect on SCFA production. *Starch-Starke* **70**, 1800037.
99. American Diabetes A (2018) 4. Lifestyle management: standards of medical care in diabetes-2018. *Diabetes Care* **41**, S38–S50.
100. Davies MJ, D'Alessio DA, Fradkin J *et al.* (2018) Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia* **61**, 2461–2498.
101. Kang X, Wang C, Lifang L *et al.* (2013) Effects of different proportion of carbohydrate in breakfast on postprandial glucose excursion in normal glucose tolerance and impaired glucose regulation subjects. *Diabetes Technol Ther* **15**, 569–574.
102. Korsmo-Haugen HK, Brurberg KG, Mann J *et al.* (2019) Carbohydrate quantity in the dietary management of type 2 diabetes: a systematic review and meta-analysis. *Diabetes Obes Metab* **21**, 15–27.
103. van Zuuren EJ, Fedorowicz Z, Kuijpers T *et al.* (2018) Effects of low-carbohydrate- compared with low-fat-diet interventions on metabolic control in people with type 2 diabetes: a systematic review including GRADE assessments. *Am J Clin Nutr* **108**, 300–331.
104. Snorgaard O, Poulsen GM, Andersen HK *et al.* (2017) Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes. *BMJ Open Diabetes Res Care* **5**, e000354.
105. McCombie L, Leslie W, Taylor R *et al.* (2017) Beating type 2 diabetes into remission. *Br Med J* **358**, j4030.
106. Buse JB, Caprio S, Cefalu WT *et al.* (2009) How do we define cure of diabetes? *Diabetes Care* **32**, 2133–2135.
107. Sato J, Kanazawa A, Makita S *et al.* (2017) A randomized controlled trial of 130g/day low-carbohydrate diet in type 2 diabetes with poor glycemic control. *Clin Nutr* **36**, 992–1000.
108. Skytte MJ, Samkani A, Petersen AD *et al.* (2019) A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial. *Diabetologia* **62**, 2066–2078.
109. Gannon MC & Nuttall FQ (2004) Effect of a high-protein, low-carbohydrate diet on blood glucose control in people with type 2 diabetes. *Diabetes* **53**, 2375–2382.
110. Kitabchi AE, McDaniel KA, Wan JY *et al.* (2013) Effects of high-protein versus high-carbohydrate diets on markers of beta-cell function, oxidative stress, lipid peroxidation, proinflammatory cytokines, and adipokines in obese, premenopausal women without diabetes: a randomized controlled trial. *Diabetes Care* **36**, 1919–1925.
111. Newsholme P & Krause M (2012) Nutritional regulation of insulin secretion: implications for diabetes. *Clin Biochem Rev* **33**, 35–47.
112. Thomas FB, Mazzaferri EL, Crockett SE *et al.* (1976) Stimulation of secretion of gastric inhibitory polypeptide and insulin by intraduodenal amino acid perfusion. *Gastroenterology* **70**, 523–527.
113. Trico D, Frascerra S, Baldi S *et al.* (2019) The insulinotropic effect of a high-protein nutrient preload is mediated by the increase of plasma amino acids in type 2 diabetes. *Eur J Nutr* **58**, 2253–2261.
114. Wycherley TP, Thompson CH, Buckley JD *et al.* (2016) Long-term effects of weight loss with a very-low carbohydrate, low saturated fat diet on flow mediated dilatation in patients with type 2 diabetes: a randomised controlled trial. *Atherosclerosis* **252**, 28–31.
115. Oyabu C, Hashimoto Y, Fukuda T *et al.* (2016) Impact of low-carbohydrate diet on renal function: a meta-analysis of over 1000 individuals from nine randomised controlled trials. *Br J Nutr* **116**, 632–638.
116. Palma-Duran SA, Vlassopoulos A, Lean M *et al.* (2017) Nutritional intervention and impact of polyphenol on glycohemoglobin (HbA1c) in non-diabetic and type 2 diabetic subjects: systematic review and meta-analysis. *Crit Rev Food Sci Nutr* **57**, 975–986.
117. Vlassopoulos A, Lean ME & Combet E (2014) Protein-phenolic interactions and inhibition of glycation – combining a systematic review and experimental models for enhanced physiological relevance. *Food Funct* **5**, 2646–2655.
118. Churuangasuk C, Griffiths D, Lean MEJ *et al.* (2019) Impacts of carbohydrate-restricted diets on micronutrient intakes and status: a systematic review. *Obes Rev* **20**, 1132–1147.
119. Bazzano LA, Hu T, Reynolds K *et al.* (2014) Effects of low-carbohydrate and low-fat diets: a randomized trial. *Ann Intern Med* **161**, 309–318.
120. Gardner CD, Kim S, Bersamin A *et al.* (2010) Micronutrient quality of weight-loss diets that focus on macronutrients: results from the A TO Z study. *Am J Clin Nutr* **92**, 304–312.
121. Genoni A, Lyons-Wall P, Lo J *et al.* (2016) Cardiovascular, metabolic effects and dietary composition of ad-libitum paleolithic vs. Australian guide to healthy eating diets: a 4-week randomised trial. *Nutrients* **8**, 314.
122. Johnstone AM, Lobley GE, Horgan GW *et al.* (2011) Effects of a high-protein, low-carbohydrate v. high-protein, moderate-carbohydrate weight-loss diet on antioxidant status, endothelial markers and plasma indices of the cardiometabolic profile. *Br J Nutr* **106**, 282–291.
123. Manousou S, Stal M, Larsson C *et al.* (2018) A Paleolithic-type diet results in iodine deficiency: a 2-year randomized trial in postmenopausal obese women. *Eur J Clin Nutr* **72**, 124–129.
124. Truby H, Hiscutt R, Herriot AM *et al.* (2008) Commercial weight loss diets meet nutrient requirements in free living adults over 8 weeks: a randomised controlled weight loss trial. *Nutr J* **7**, 25.
125. Mardinoglu A, Wu H, Bjornson E *et al.* (2018) An integrated understanding of the rapid metabolic benefits of a carbohydrate-restricted diet on hepatic steatosis in humans. *Cell Metab* **27**, 559–571.
126. Miller BV, Bertino JS, Reed RG *et al.* (2003) An evaluation of the Atkins' diet. *Metab Syndr Relat Disord* **1**, 299–309.

127. Elidottir AS, Halldorsson TI, Gunnarsdottir I *et al.* (2016) Dietary intake and cardiovascular risk factors in icelanders following voluntarily a low carbohydrate diet. *PLoS One* **11**, e0156655.
128. Hoyt CS, III & Billson FA (1977) Low-carbohydrate diet optic neuropathy. *Med J Aust* **1**, 65–66.
129. McKenna LA, Drummond RS, Drummond S *et al.* (2013) Seeing double: the low carb diet. *Br Med J* **346**, f2563.
130. Gernand AD, Schulze KJ, Stewart CP *et al.* (2016) Micronutrient deficiencies in pregnancy worldwide: health effects and prevention. *Nat Rev Endocrinol* **12**, 274–289.
131. Ference BA, Ginsberg HN, Graham I *et al.* (2017) Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J* **38**, 2459–2472.
132. Goldstein JL & Brown MS (2015) A century of cholesterol and coronaries: from plaques to genes to statins. *Cell* **161**, 161–172.
133. Hu T, Mills KT, Yao L *et al.* (2012) Effects of low-carbohydrate diets versus low-fat diets on metabolic risk factors: a meta-analysis of randomized controlled clinical trials. *Am J Epidemiol* **176**(Suppl. 7), S44–S54.
134. Mangravite LM, Chiu S, Wojnoonski K *et al.* (2011) Changes in atherogenic dyslipidemia induced by carbohydrate restriction in men are dependent on dietary protein source. *J Nutr* **141**, 2180–2185.
135. Barnett TD, Barnard ND & Radak TL (2009) Development of symptomatic cardiovascular disease after self-reported adherence to the Atkins diet. *J Am Diet Assoc* **109**, 1263–1265.
136. Sheikh M, Chahal M, Rock-Willoughby J *et al.* (2014) Carbohydrate-restricted diet and acute coronary syndrome: a case report and review of this conflicting and yet unknown association. *Am J Ther* **21**, e41–e44.
137. von Geijer L & Ekelund M (2015) Ketoacidosis associated with low-carbohydrate diet in a non-diabetic lactating woman: a case report. *J Med Case Rep* **9**, 224.
138. Churuangasuk C, Lean MEJ & Combet E (2019) Lower carbohydrate and higher fat intakes are associated with higher hemoglobin A1c: findings from the UK National Diet and Nutrition Survey 2008–2016. *Eur J Nutr* [Epublication ahead of print version].
139. de Koning L, Fung TT, Liao X *et al.* (2011) Low-carbohydrate diet scores and risk of type 2 diabetes in men. *Am J Clin Nutr* **93**, 844–850.
140. Namazi N, Larijani B & Azadbakht L (2017) Low-carbohydrate-diet score and its association with the risk of diabetes: a systematic review and meta-analysis of cohort studies. *Horm Metab Res* **49**, 565–571.
141. Vlassopoulos A, Lean ME & Combet E (2013) Role of oxidative stress in physiological albumin glycation: a neglected interaction. *Free Radic Biol Med* **60**, 318–324.
142. Rayner J, D'Arcy E, Ross LJ *et al.* (2020) Carbohydrate restriction in midlife is associated with higher risk of type 2 diabetes among Australian women: a cohort study. *Nutr Metab Cardiovasc Dis* **30**, 400–409.
143. Noto H, Goto A, Tsujimoto T *et al.* (2016) Long-term low-carbohydrate diets and type 2 diabetes risk: a systematic review and meta-analysis of observational studies. *J Gen Fam Med* **17**, 60–70.
144. Ericson U, Rukh G, Stojkovic I *et al.* (2013) Sex-specific interactions between the IRS1 polymorphism and intakes of carbohydrates and fat on incident type 2 diabetes. *Am J Clin Nutr* **97**, 208–216.
145. Schulze MB, Schulz M, Heidemann C *et al.* (2008) Carbohydrate intake and incidence of type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. *Br J Nutr* **99**, 1107–1116.
146. Simila ME, Kontto JP, Valsta LM *et al.* (2012) Carbohydrate substitution for fat or protein and risk of type 2 diabetes in male smokers. *Eur J Clin Nutr* **66**, 716–721.
147. Sluijs I, Beulens JW, van der Schouw YT *et al.* (2013) Dietary glycemic index, glycemic load, and digestible carbohydrate intake are not associated with risk of type 2 diabetes in eight European countries. *J Nutr* **143**, 93–99.
148. Nanri A, Mizoue T, Kurotani K *et al.* (2015) Low-carbohydrate diet and type 2 diabetes risk in Japanese men and women: the Japan Public Health Center-Based Prospective Study. *PLoS One* **10**, e0118377.
149. Villegas R, Liu S, Gao YT *et al.* (2007) Prospective study of dietary carbohydrates, glycemic index, glycemic load, and incidence of type 2 diabetes mellitus in middle-aged Chinese women. *Arch Intern Med* **167**, 2310–2316.
150. Sun Q, Spiegelman D, van Dam RM *et al.* (2010) White rice, brown rice, and risk of type 2 diabetes in US men and women. *Arch Intern Med* **170**, 961–969.
151. Bao W, Li S, Chavarro JE *et al.* (2016) Low carbohydrate-diet scores and long-term risk of type 2 diabetes among women with a history of gestational diabetes mellitus: a prospective cohort study. *Diabetes Care* **39**, 43–49.
152. Halton TL, Liu S, Manson JE *et al.* (2008) Low-carbohydrate-diet score and risk of type 2 diabetes in women. *Am J Clin Nutr* **87**, 339–346.
153. Tramunt B, Smati S, Grandgeorge N *et al.* (2020) Sex differences in metabolic regulation and diabetes susceptibility. *Diabetologia* **63**, 453–461.
154. Halton TL, Willett WC, Liu S *et al.* (2006) Low-carbohydrate-diet score and the risk of coronary heart disease in women. *N Engl J Med* **355**, 1991–2002.
155. Lagiou P, Sandin S, Lof M *et al.* (2012) Low carbohydrate-high protein diet and incidence of cardiovascular diseases in Swedish women: prospective cohort study. *Br Med J* **344**, e4026.
156. Zhang S, Zhuang X, Lin X *et al.* (2019) Low-carbohydrate diets and risk of incident atrial fibrillation: a prospective cohort study. *J Am Heart Assoc* **8**, e011955.
157. Lagiou P, Sandin S, Weiderpass E *et al.* (2007) Low carbohydrate-high protein diet and mortality in a cohort of Swedish women. *J Intern Med* **261**, 366–374.
158. Trichopoulou A, Psaltopoulou T, Orfanos P *et al.* (2007) Low-carbohydrate-high-protein diet and long-term survival in a general population cohort. *Eur J Clin Nutr* **61**, 575–581.
159. Fung TT, van Dam RM, Hankinson SE *et al.* (2010) Low-carbohydrate diets and all-cause and cause-specific mortality: two cohort studies. *Ann Intern Med* **153**, 289–298.
160. Sjogren P, Becker W, Warensjo E *et al.* (2010) Mediterranean and carbohydrate-restricted diets and mortality among elderly men: a cohort study in Sweden. *Am J Clin Nutr* **92**, 967–974.
161. Nilsson LM, Winkvist A, Eliasson M *et al.* (2012) Low-carbohydrate, high-protein score and mortality in



- a northern Swedish population-based cohort. *Eur J Clin Nutr* **66**, 694–700.
162. Noto H, Goto A, Tsujimoto T *et al.* (2013) Low-carbohydrate diets and all-cause mortality: a systematic review and meta-analysis of observational studies. *PLoS One* **8**, e55030.
163. Seidelmann SB, Claggett B, Cheng S *et al.* (2018) Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis. *Lancet Public Health* **3**, e419–e428.
164. Dehghan M, Mente A, Zhang X *et al.* (2017) Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. *Lancet* **390**, 2050–2062.
165. Li S, Flint A, Pai JK *et al.* (2014) Low carbohydrate diet from plant or animal sources and mortality among myocardial infarction survivors. *J Am Heart Assoc* **3**, e001169.
166. Jallinoja P, Niva M, Helakorpi S *et al.* (2014) Food choices, perceptions of healthiness, and eating motives of self-identified followers of a low-carbohydrate diet. *Food Nutr Res* **58**, 23552.
167. Feinman RD, Vernon MC & Westman EC (2006) Low carbohydrate diets in family practice: what can we learn from an internet-based support group. *Nutr J* **5**, 26.
168. Collins CB, Winham DM, Hutchins AM *et al.* (2006) Dietary intake, characteristics, and attitudes of self-reported low-carbohydrate dieters. *FASEB J* **20**, A575–A575.
169. Zinn C, Rush A & Johnson R (2018) Assessing the nutrient intake of a low-carbohydrate, high-fat (LCHF) diet: a hypothetical case study design. *BMJ Open* **8**, e018846.